Corpus Intelligence IC Memo — SALEM MEDICAL CENTER 2026-04-26 17:22 UTC
IC Memo — SALEM MEDICAL CENTER
Investment Committee Memorandum | NJ | 113 beds | Grade C | EBITDA uplift $2.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SALEM MEDICAL CENTER

CCN 310091 | SALEM, NJ | 113 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SALEM MEDICAL CENTER is a 113-bed under-performing / distressed in SALEM, NJ with $38.0M in net patient revenue and a -38.1% operating margin. The hospital serves a payer mix of 40.3% Medicare, 4.5% Medicaid, and 55.3% commercial.

Thesis: Undervalued. Our ML models identify $2.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -38.1% to -30.8% (+736bps).

Net Revenue HCRIS$38.0M
Current EBITDA COMPUTED$-14.5M
Operating Margin COMPUTED-38.1%
Occupancy HCRIS19.8%
Revenue / Bed COMPUTED$337K
Net-to-Gross HCRIS11.2%
Distress Probability ML55.0%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
50
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -38.1% places it below the state median. Among 50 size-comparable peers (56-226 beds), the median margin is -5.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (56-226), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SALEM MEDICAL CENTER (Target)NJ113$38.0M-38.1%
CAPITAL HEALTH MED CENTER - HONJ209$746.8M0.8%
PRINCETON HEALTHCARE SYSTEMNJ206$587.8M-5.7%
HELENE FULD MEDICAL CENTERNJ162$430.2M-3.2%
HUNTERDON MEDICAL CENTERNJ184$358.4M-9.6%
MOUNTAINSIDE HOSPITALNJ184$306.3M12.2%
ST. CLARES HOSPITALNJ217$291.4M-0.2%
TRINITAS HOSPITALNJ192$256.4M-27.3%
CHILTON HOSPITALNJ198$253.5M4.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$799K+210bp18mo
Cost to Collect4.5%2.5%$761K+200bp12mo
Denial Rate Reduction12.0%6.5%$753K+198bp12mo
A/R Days Reduction5200.0%3800.0%$463K+122bp9mo
Clean Claim Rate88.0%96.0%$24K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$799K
Cost to Collect
$761K
Denial Rate Reduction
$753K
A/R Days Reduction
$463K
Clean Claim Rate
$24K
Total EBITDA Uplift$2.8M
Current EBITDA$-14.5M
+ RCM Uplift+$2.8M
Pro Forma EBITDA$-11.7M
Current Margin-38.1%
Pro Forma Margin-30.8%
WC Released (1x)$1.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-22.3M$-67.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-22.3M$-81.7M0.00x-100.0%
Bull Case9.0x11.0x$-20.1M$-79.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-20.1M$-92.8M0.00x-100.0%
Bear Case11.0x10.0x$-24.5M$-74.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-24.5M$-89.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 19.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 55.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 56-226 beds
  • Same-state prioritization (n=51)
  • Comp margins: P25=-25.8% / P50=-5.6% / P75=2.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.